<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558814</url>
  </required_header>
  <id_info>
    <org_study_id>Galectin-9 in SLE</org_study_id>
    <nct_id>NCT04558814</nct_id>
  </id_info>
  <brief_title>Evaluation of Serum Galectin-9 Level in Systemic Lupus Erythematosus Patients and it's Association With Disease Activity and Organ Damage</brief_title>
  <official_title>Evaluation of Serum Galectin-9 Level in Systemic Lupus Erythematosus Patients and it's Association With Disease Activity and Organ Damage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study aims to evaluate serum galectin-9 in systemic lupus erythematosus patients and&#xD;
      determine it's correlation with overall disease process&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by producing large&#xD;
      quantities of antibodies directed against self-antigens, particularly double stranded DNA&#xD;
      (dsDNA) and small nuclear RNA-binding proteins such as Ro, La, Sm, and nRNP.&#xD;
&#xD;
      SLE-associated autoantibodies and high serum interferon alpha (IFN-α) are two important&#xD;
      heritable phenotypes in SLE which are thought to play a role in disease pathogenesis . The&#xD;
      most remarkable feature of the anti DNA response is its association with immunopathologic&#xD;
      events especially glomerulonephritis . Immune complexes containing DNA can promote the&#xD;
      expression of interferon alpha (IFN-alpha) by a specialized population of dendritic cells&#xD;
      known as plasmacytoid dendritic cells .&#xD;
&#xD;
      Activation of the type I interferon (IFN) system is associated with disease pathogenesis in&#xD;
      SLE, with affected patients typically demonstrating high concentrations of type I IFN&#xD;
      proteins . Overexpression of type I IFN-induced genes that includes hundreds of gene&#xD;
      transcripts; which is termed interferon signature (IFNGS), has been observed in 60-80% of&#xD;
      adults and the majority of children with SLE .&#xD;
&#xD;
      Galectin-9 (Gal-9) is recognized as a novel, easy to measure biomarker for type1 IFN&#xD;
      signatures and galectin-9 could aid in clinical decision making in SLE as a marker for&#xD;
      disease activity and organ damage.&#xD;
&#xD;
      Galectin-9 is expressed by T cells, macro-phages, fibroblasts, and endothelial cells, its&#xD;
      secreted form is barely detected under physiological conditions, it plays an recognizable&#xD;
      role in the regulation of inflammation and immune responses by down-regulating&#xD;
      pro-inflammatory T cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate serum galectin-9 level in SLE patients and compare it with the serum galectin-9 level in healthy controls.</measure>
    <time_frame>One year</time_frame>
    <description>Compare level of galectin-9 in SLE patients with that of healthy controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>compare galectin-9 in SLE patients with active and inactive renal disease.</measure>
    <time_frame>One year</time_frame>
    <description>Comparison of marker level between patients with active renal disease and patients without a tive renal disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Systemic lupus erythematosus patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Evaluation of serum galectin-9 level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Evaluation of serum galectin-9 level</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum galectin-9 level</intervention_name>
    <description>Determining level of galectin-9 in sera of patients of SLE with different disease activity and organ affection and Sera of control group</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Systemic lupus erythematosus patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinically diagnosed systemic lupus erythematosus patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with other autoimmune diseases: 1)rheumatoid arthritis patients&#xD;
             2)dermatomyositis 3)scleroderma 4)mixed connective tissue disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona Hussein, Doctor</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Reem Hossam Abd El-rahman, Master</last_name>
    <phone>01033992163</phone>
    <email>medohossamkikii@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Essam Ahmed Mohamed abda, Professor</last_name>
    <phone>01003889450</phone>
    <email>essamabda@hotmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Muslimov IA, Iacoangeli A, Eom T, Ruiz A, Lee M, Stephenson S, Ginzler EM, Tiedge H. Neuronal BC RNA Transport Impairments Caused by Systemic Lupus Erythematosus Autoantibodies. J Neurosci. 2019 Sep 25;39(39):7759-7777. doi: 10.1523/JNEUROSCI.1657-18.2019. Epub 2019 Aug 12.</citation>
    <PMID>31405929</PMID>
  </results_reference>
  <results_reference>
    <citation>Catalina MD, Bachali P, Geraci NS, Grammer AC, Lipsky PE. Gene expression analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus. Commun Biol. 2019 Apr 23;2:140. doi: 10.1038/s42003-019-0382-x. eCollection 2019.</citation>
    <PMID>31044165</PMID>
  </results_reference>
  <results_reference>
    <citation>Kudose S, Santoriello D, Bomback AS, Stokes MB, D'Agati VD, Markowitz GS. Sensitivity and Specificity of Pathologic Findings to Diagnose Lupus Nephritis. Clin J Am Soc Nephrol. 2019 Nov 7;14(11):1605-1615. doi: 10.2215/CJN.01570219. Epub 2019 Oct 25.</citation>
    <PMID>31653670</PMID>
  </results_reference>
  <results_reference>
    <citation>Rönnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med. 2019 Aug 13;6(1):e000270. doi: 10.1136/lupus-2018-000270. eCollection 2019. Review.</citation>
    <PMID>31497305</PMID>
  </results_reference>
  <results_reference>
    <citation>Matta B, Barnes BJ. Coordination between innate immune cells, type I IFNs and IRF5 drives SLE pathogenesis. Cytokine. 2020 Aug;132:154731. doi: 10.1016/j.cyto.2019.05.018. Epub 2019 May 23. Review.</citation>
    <PMID>31130331</PMID>
  </results_reference>
  <results_reference>
    <citation>Brohawn PZ, Streicher K, Higgs BW, Morehouse C, Liu H, Illei G, Ranade K. Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures. Lupus. 2019 Nov;28(13):1524-1533. doi: 10.1177/0961203319885447. Epub 2019 Oct 29.</citation>
    <PMID>31660791</PMID>
  </results_reference>
  <results_reference>
    <citation>Matsuoka N, Fujita Y, Temmoku J, Furuya MY, Asano T, Sato S, Matsumoto H, Kobayashi H, Watanabe H, Suzuki E, Kozuru H, Yastuhashi H, Migita K. Galectin-9 as a biomarker for disease activity in systemic lupus erythematosus. PLoS One. 2020 Jan 27;15(1):e0227069. doi: 10.1371/journal.pone.0227069. eCollection 2020.</citation>
    <PMID>31986153</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen HY, Wu YF, Chou FC, Wu YH, Yeh LT, Lin KI, Liu FT, Sytwu HK. Intracellular Galectin-9 Enhances Proximal TCR Signaling and Potentiates Autoimmune Diseases. J Immunol. 2020 Mar 1;204(5):1158-1172. doi: 10.4049/jimmunol.1901114. Epub 2020 Jan 22.</citation>
    <PMID>31969388</PMID>
  </results_reference>
  <results_reference>
    <citation>Vilar KM, Pereira MC, Tavares Dantas A, de Melo Rêgo MJB, Pitta IDR, Pinto Duarte ÂLB, da Rocha Pitta MG. Galectin-9 gene (LGALS9) polymorphisms are associated with rheumatoid arthritis in Brazilian patients. PLoS One. 2019 Oct 10;14(10):e0223191. doi: 10.1371/journal.pone.0223191. eCollection 2019.</citation>
    <PMID>31600237</PMID>
  </results_reference>
  <results_reference>
    <citation>Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86. doi: 10.1002/art.34473.</citation>
    <PMID>22553077</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>RHAbdelrahman</investigator_full_name>
    <investigator_title>Resident doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

